Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN Astrazeneca	$186.06 +2.3%	$190.77	$137.23 ▼ $212.71	$288.57B	0.25	2.58 million shs	1.92 million shs
NVO Novo Nordisk A/S	$42.93 -1.9%	$41.49	$35.12 ▼ $81.44	$191.66B	0.78	20.50 million shs	8.44 million shs
NVS Novartis	$149.04 +0.4%	$149.60	$112.34 ▼ $170.46	$284.40B	0.46	1.97 million shs	3.03 million shs
SNY Sanofi	$45.02 +1.4%	$45.47	$42.28 ▼ $52.68	$109.15B	0.34	3.54 million shs	1.99 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN Astrazeneca	+3.09%	-2.12%	+0.20%	-6.43%	+24.47%
NVO Novo Nordisk A/S	+4.00%	-3.89%	-2.52%	+13.31%	-39.44%
NVS Novartis	+3.26%	-2.01%	+2.00%	-7.38%	+26.73%
SNY Sanofi	+4.74%	+0.20%	+2.35%	-0.38%	-10.34%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN Astrazeneca	$186.06 +2.3%	$190.77	$137.23 ▼ $212.71	$288.57B	0.25	2.58 million shs	1.92 million shs
NVO Novo Nordisk A/S	$42.93 -1.9%	$41.49	$35.12 ▼ $81.44	$191.66B	0.78	20.50 million shs	8.44 million shs
NVS Novartis	$149.04 +0.4%	$149.60	$112.34 ▼ $170.46	$284.40B	0.46	1.97 million shs	3.03 million shs
SNY Sanofi	$45.02 +1.4%	$45.47	$42.28 ▼ $52.68	$109.15B	0.34	3.54 million shs	1.99 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN Astrazeneca	+3.09%	-2.12%	+0.20%	-6.43%	+24.47%
NVO Novo Nordisk A/S	+4.00%	-3.89%	-2.52%	+13.31%	-39.44%
NVS Novartis	+3.26%	-2.01%	+2.00%	-7.38%	+26.73%
SNY Sanofi	+4.74%	+0.20%	+2.35%	-0.38%	-10.34%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZN Astrazeneca	2.85	Moderate Buy	$205.33	10.84% Upside
NVO Novo Nordisk A/S	2.13	Hold	$65.56	51.04% Upside
NVS Novartis	2.31	Hold	$141.20	-5.00% Downside
SNY Sanofi	2.47	Hold	$51.00	13.37% Upside

Current Analyst Ratings Breakdown

Latest NVS, AZN, NVO, and SNY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/1/2026	AZN Astrazeneca	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/1/2026	AZN Astrazeneca	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/21/2026	AZN Astrazeneca	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell
5/14/2026	AZN Astrazeneca	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/13/2026	SNY Sanofi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
5/13/2026	AZN Astrazeneca	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/12/2026	NVO Novo Nordisk A/S	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
5/4/2026	AZN Astrazeneca	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/1/2026	SNY Sanofi	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$52.00
5/1/2026	SNY Sanofi	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight
4/30/2026	AZN Astrazeneca	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZN Astrazeneca	$58.74B	4.89	$13.58 per share	13.64	$31.41 per share	5.90
NVO Novo Nordisk A/S	$327.80B	0.59	$4.84 per share	8.96	$6.58 per share	6.60
NVS Novartis	$56.58B	5.01	$11.11 per share	13.38	$22.04 per share	6.74
SNY Sanofi	$47.35B	2.30	$7.50 per share	6.00	$33.26 per share	1.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZN Astrazeneca	$10.23B	$6.66	27.82	17.35	1.51	17.19%	30.86%	12.68%	7/27/2026 (Estimated)
NVO Novo Nordisk A/S	$15.51B	$4.26	10.20	12.62	3.75	37.23%	63.31%	22.19%	8/5/2026 (Estimated)
NVS Novartis	$13.98B	$6.98	21.30	15.12	2.52	24.87%	38.82%	15.16%	7/21/2026 (Estimated)
SNY Sanofi	$8.84B	$3.58	12.57	8.63	1.04	16.95%	13.39%	7.58%	7/30/2026 (Estimated)

Latest NVS, AZN, NVO, and SNY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2026	Q1 2026	NVO Novo Nordisk A/S	$0.87	$1.04	+$0.17	$1.69	$10.86 billion	$10.85 billion
4/29/2026	Q1 2026	AZN Astrazeneca	$2.52	$2.58	+$0.06	$0.9850	$14.93 billion	$15.29 billion
4/27/2026	Q1 2026	NVS Novartis	$2.11	$1.99	-$0.12	$1.65	$13.44 billion	$13.52 billion
3/31/2026	Q1 2026	NVO Novo Nordisk A/S	N/A	$1.0270	N/A	$1.69	N/A	$10.85 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZN Astrazeneca	$4.34	2.34%	+2.30%	65.17%	N/A
NVO Novo Nordisk A/S	$1.74	4.01%	+21.74%	40.85%	N/A
NVS Novartis	$3.08	2.07%	+5.28%	44.13%	N/A
SNY Sanofi	$1.76	3.91%	+6.46%	49.16%	N/A

Latest NVS, AZN, NVO, and SNY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/14/2026	SNY Sanofi	annual	$2.4225	5.59%	5/4/2026	5/4/2026	6/3/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZN Astrazeneca	0.52	0.91	0.71
NVO Novo Nordisk A/S	0.59	0.79	0.56
NVS Novartis	0.96	0.85	0.65
SNY Sanofi	0.17	1.01	0.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZN Astrazeneca	20.35%
NVO Novo Nordisk A/S	11.54%
NVS Novartis	13.12%
SNY Sanofi	14.03%

Insider Ownership

Company	Insider Ownership
AZN Astrazeneca	N/A
NVO Novo Nordisk A/S	0.07%
NVS Novartis	0.01%
SNY Sanofi	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZN Astrazeneca	96,100	1.55 billion	N/A	N/A
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable
NVS Novartis	75,267	1.91 billion	1.91 billion	Optionable
SNY Sanofi	74,846	2.42 billion	2.40 billion	Optionable

NVO, NVS, AZN, and SNY Headlines

Recent News About These Companies

Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi

June 5 at 7:00 AM | businesswire.com

Sanofi Stock Falls 6% in 3 Months: Should You Buy, Sell or Hold?

June 4 at 10:10 AM | zacks.com

Press Release: Sanofi launches 2026 global employee stock purchase plan

June 4 at 4:07 AM | globenewswire.com

Is Sanofi (SNY) Approaching a Breakthrough in Rare Neurological Disease Treatment?

June 2 at 8:27 PM | finance.yahoo.com

FDA Grants Priority Review to SNY's Filing for Gaucher Disease Drug

May 29, 2026 | zacks.com

Sanofi: Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease

May 28, 2026 | finanznachrichten.de

Press Release: Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease

May 28, 2026 | globenewswire.com

Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails

May 22, 2026 | zacks.com

sanofi - SNY

May 21, 2026 | foxbusiness.com

Sanofi: Information concerning the total number of voting rights and shares - April 2026

May 19, 2026 | globenewswire.com

Teva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?

May 19, 2026 | zacks.com

Sanofi says rare lung disease drug outperforms standard care in trial

May 18, 2026 | reuters.com

Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD

May 18, 2026 | globenewswire.com

3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally

May 13, 2026 | fool.com

Erste Group Bank Decreases Earnings Estimates for Sanofi

May 11, 2026 | marketbeat.com

DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects

May 8, 2026 | zacks.com

Truist Financial Corp Sells 37,780 Shares of Sanofi $SNY

May 7, 2026 | marketbeat.com

Sanofi asks to pull diabetes drug out of FDA voucher program, STAT News reports

May 6, 2026 | reuters.com

Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1

May 6, 2026 | prnewswire.com

Sanofi $SNY Shares Sold by UBS Group AG

May 6, 2026 | marketbeat.com

Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi

April 29, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NVO, NVS, AZN, and SNY Company Descriptions

Astrazeneca NYSE:AZN

$186.06 +4.26 (+2.35%)

Closing price 03:59 PM Eastern

Extended Trading

$184.67 -1.39 (-0.75%)

As of 04:04 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Novo Nordisk A/S NYSE:NVO

$42.92 -0.83 (-1.89%)

Closing price 03:59 PM Eastern

Extended Trading

$42.95 +0.03 (+0.06%)

As of 04:04 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novartis NYSE:NVS

$149.04 +0.64 (+0.43%)

Closing price 03:59 PM Eastern

Extended Trading

$148.50 -0.54 (-0.36%)

As of 04:04 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Sanofi NASDAQ:SNY

$45.02 +0.64 (+1.45%)

Closing price 03:59 PM Eastern

Extended Trading

$45.02 0.00 (0.00%)

As of 04:04 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NVS, AZN, NVO, and SNY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NVS, AZN, NVO, and SNY Earnings

Compare Dividends

Latest NVS, AZN, NVO, and SNY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NVO, NVS, AZN, and SNY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NVO, NVS, AZN, and SNY Company Descriptions

Astrazeneca NYSE:AZN

Novo Nordisk A/S NYSE:NVO

Novartis NYSE:NVS

Sanofi NASDAQ:SNY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools